Abstract A030: Evaluation of phosphoprotein- and transcript-based pharmacodynamic biomarkers in pre-clinical studies of the novel SOS1::KRAS inhibitor BI-3406

KRAS is among the most frequently mutated oncogenes across all human cancers. Targeting KRAS-mutant cancers either directly or at the effector level has so far failed in the clinic, with adoptive responses and toxicities being the major limiting factors. Nevertheless, direct targeting of the mutant KRAS-G12C allele has shown promising results in early clinical trials. BI-3406 is an inhibitor of the interaction between KRAS and its Guanine...